Welcome to our dedicated page for Cno Finl Group SEC filings (Ticker: CNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CNO Financial Group, Inc. (NYSE: CNO) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret them. As a life and health insurer and financial services provider focused on middle-income America, CNO uses its filings to present detailed information on its insurance products, capital position and operating performance.
Investors can review CNO’s current reports on Form 8-K, which the company uses to furnish quarterly earnings press releases, quarterly financial supplements and additional financial and operating data. These filings commonly include metrics such as net income, net operating income, income from insurance products across annuity, health and life lines, fee income, investment income not allocated to product lines, and measures like book value per share and operating return on equity.
Over time, CNO’s SEC filings also provide insight into capital management and structure, including common stock dividends, share repurchase activity, reinsurance transactions with its wholly owned Bermuda reinsurance company, and technology modernization initiatives such as the TechMod project. Filings may describe changes in business mix, such as the decision to exit the fee services side of the Worksite Division to focus on core insurance offerings.
On Stock Titan, AI-generated highlights help explain the key points in lengthy documents, so users can quickly understand what each filing means for CNO’s insurance operations, investment portfolio and shareholders. Real-time updates from EDGAR ensure that new 8-Ks and other forms appear promptly, while tools for viewing insider-related information, capital actions and recurring reporting patterns make it easier to analyze CNO’s regulatory history.
CNO Financial Group, Inc. insider reports charitable stock donation
An officer of CNO Financial Group, Inc. (ticker CNO), identified as the President, Worksite Division, reported a charitable donation of company stock. On 11/25/2025, the insider disposed of 1,500 shares of CNO common stock in a transaction coded "G," which denotes a charitable gift, at a reported price of $0 per share. Following this transaction, the insider directly beneficially owns 40,355 shares of CNO common stock. The filing shows no derivative security transactions and indicates the report is filed by one reporting person.
CNO Financial Group has a planned insider sale of up to 3,000 shares of its common stock, with an aggregate market value of $123,000, as disclosed in a Form 144 notice. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 11/24/2025. These securities were acquired from the issuer on 01/02/2024 as 1,800 performance shares and 1,200 shares of restricted stock, both fully paid. Shares of CNO common stock outstanding were 95,353,512 as of the figure reported, which serves as a baseline ownership context.
CNO Financial Group, Inc. CEO and director Gary C. Bhojwani reported a sale of company stock. On 11/20/2025, he sold 31,430 shares of common stock at a weighted average price of $39.9727 per share in an open market transaction coded as a sale. After this transaction, he beneficially owns 227,356 shares directly and 635,471 shares indirectly through the Gary C. Bhojwani Revocable Trust. The filing notes that the shares were sold pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025, with sales executed at prices ranging from $39.49 to $40.465 per share.
CNO Financial Group, Inc. filed a Form 4 reporting a charitable stock donation by its Chief Financial Officer. On 11/20/2025, the CFO disposed of 3,740 shares of CNO common stock in a transaction coded "G," which the filing identifies as a charitable donation at a price of $0 per share. After this transaction, the reporting person directly beneficially owns 195,467.077 shares of CNO common stock. The filing is made by one reporting person and reflects a personal charitable transfer rather than an open-market sale.
A shareholder of CNO (symbol CNO) filed a Form 144 notice indicating an intention to sell 31,430 shares of CNO common stock through Morgan Stanley Smith Barney LLC on the NYSE. The filing lists an aggregate market value of
CNO Financial Group reported an insider stock transaction by its General Counsel. On 11/17/2025, the officer made a charitable donation of 2,000 shares of CNO common stock, recorded with transaction code G and a reported price of $0. After this donation, the officer directly beneficially owns 275,916 shares of CNO common stock. The filing reflects a routine change in ownership rather than an open-market purchase or sale.
CNO Financial Group (CNO) disclosed an insider transaction by its Chief Investment Officer. On 11/10/2025, the executive exercised 71,400 employee stock options at an exercise price of $17.38 per share and then sold 48,665 shares at a $41.2414 weighted average price to cover the exercise price and required taxes. Following these transactions, the executive beneficially owned 671,542 shares directly. The options relate to grants that vested on 02/23/2018 and 02/23/2019 and expire on 02/23/2026. Sales occurred between $41.00 and $41.57 per share.
CNO: A holder filed a Form 144 notice to sell up to 48,665 shares of common stock, with an aggregate market value $2,007,012.73. The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services as broker, an approximate sale date of 11/10/2025, and the NYSE as the exchange.
The shares were acquired via a stock option exercise on 11/10/2025 with cash payment. Shares outstanding were 95,353,512, providing baseline context.
CNO Financial Group reported Q3 2025 net income of $23.1 million, or $0.24 per diluted share, up from $9.3 million a year earlier, as revenues grew to $1,188.7 million from $1,129.6 million.
For the first nine months of 2025, net income fell to $136.4 million from $237.9 million, largely due to a $96.7 million non-cash impairment that fully wrote off goodwill of $69.5 million and $27.2 million of other intangibles tied to the Optavise benefits business.
At September 30, 2025, total assets were $38,296.2 million, with investments of $29,177.1 million and shareholders’ equity of $2,611.0 million. Operating cash flow for the nine-month period was $480.0 million, while the company returned capital via $259.9 million of share repurchases and $50.0 million in common dividends.